Vivos Study Bolsters Device Efficacy, Challenges CPAP Dominance
Event summary
- A study published in the Journal of Clinical Medicine confirms a correlation between oral anatomy (narrow palates, recessed jaws) and the severity of obstructive sleep apnea (OSA).
- Vivos Therapeutics’ CARE devices have received FDA 510(k) clearance for treating severe OSA in adults and moderate-to-severe OSA in children (ages 6-17), a unique regulatory distinction.
- The study, involving 100 patients, found a strong association (p<0.001) between craniofacial parameters and OSA severity, as measured by the Apnea-Hypopnea Index (AHI).
- Vivos estimates that several million Americans will undergo sleep tests annually, with nearly half testing positive for OSA, a market largely served by CPAP.
The big picture
Vivos is positioned to capitalize on a significant unmet need within the sleep apnea treatment market, where CPAP’s high abandonment rate creates an opportunity for alternative, potentially curative, solutions. The company’s FDA clearance and the supporting study provide a strong foundation, but its success hinges on demonstrating long-term efficacy and achieving widespread adoption among both providers and patients. The $30 billion sleep apnea market is ripe for disruption, but Vivos faces an uphill battle against entrenched practices and established competitors.
What we're watching
- Market Adoption
- The pace at which Vivos CARE devices can displace CPAP as the primary treatment option will depend on provider adoption and patient willingness to transition from a familiar, albeit often problematic, standard of care.
- Regulatory Scrutiny
- Continued regulatory scrutiny of Vivos’ devices and treatment protocols is likely, particularly given the unprecedented clearance for severe OSA, and could impact commercialization efforts.
- Clinical Validation
- Further clinical validation of Vivos’ methodology and long-term efficacy data will be critical to solidify its position and attract broader payer coverage.
Related topics